I'd have liked MMSE to have been as measurably responsive as the ADCS-ADL. With placebo controls the baseline for the latter can shift more and net benefit might not prove out. So we'll have to see.
I'm recalling from past presentations that ApoE4 was not a factor in the efficacy of 2-73. Several of the patients, expressing the ApoE4 gene, responded well to 2-73, at appropriate serum levels.